By Prof. Em. Tomas J. Philipson
Not vice versa.
Conventional wisdom holds that prices for prescription drugs paid by our government are substantially higher in the United States than abroad. This has led to various forms of price controls on drugs in the U.S., first through the Inflation Reduction Act and recently through proposals for Most Favored Nation (MFN) pricing whereby U.S. public payers should have the most favorable pricing.
Read the full article here.